Research ArticleOriginal Article

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen and Frankie KF Mo
Cancer Biology & Medicine August 2021, 18 (3) 825-832; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0241

References

  1. 1.↵
    2. Coates A,
    3. Abraham A,
    4. Kaye SB,
    5. Sowerbutts T,
    6. Frewin C,
    7. Fox RM, et al.
    On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19: 203–8.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Griffin AM,
    3. Butow PN,
    4. Coates AS,
    5. Childs AM,
    6. Ellis PM,
    7. Dunn SM, et al.
    On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7: 189–95.
    OpenUrlPubMedWeb of Science
  3. 3.↵
    2. Lau TKH,
    3. Yip CHW,
    4. Yeo W.
    State of the art antiemetic therapy for cancer patients. Curr Oncol Rep. 2016; 18: 2.
    OpenUrl
  4. 4.↵
    2. Hesketh PJ,
    3. Kris MG,
    4. Basch E,
    5. Bohlke K,
    6. Barbour SY,
    7. Clark-Snow RA, et al.
    Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35: 3240–61.
    OpenUrlPubMed
  5. 5.
    2. Herrstedt J,
    3. Roila F,
    4. Warr D,
    5. Celio L,
    6. Navari RM,
    7. Hesketh PJ, et al.
    Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017; 25: 277–8.
    OpenUrl
  6. 6.↵
    National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Antiemesis Version 1. 2020 https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
  7. 7.↵
    2. Yeo W,
    3. Mo FK,
    4. Suen JJ,
    5. Ho WM,
    6. Chan SL,
    7. Lau W, et al.
    A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009; 113: 529–35.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Yeo W,
    3. Lau TK,
    4. Li L,
    5. Lai KT,
    6. Pang E,
    7. Cheung M, et al.
    A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020; 50: 30–8.
    OpenUrl
  9. 9.↵
    2. Yeo W,
    3. Lau TK,
    4. Kwok CC,
    5. Lai KT,
    6. Chan VT,
    7. Li L, et al.
    NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Support Palliat Care. 2020; 1: 1–7 doi:10.1136/bmjspcare-2019-002037.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Martin AR,
    3. Pearson JD,
    4. Cai B,
    5. Elmer M,
    6. Horgan K,
    7. Lindley C, et al.
    Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003; 11: 522–7.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    2. Warr DG,
    3. Hesketh PJ,
    4. Gralla RJ,
    5. Muss HB,
    6. Herrstedt J,
    7. Eisenberg PD, et al.
    Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23: 2822–30.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Hashimoto H,
    3. Abe M,
    4. Tokuyama O,
    5. Mizutani H,
    6. Uchitomi Y,
    7. Yamaguchi T, et al.
    Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21: 242–9.
    OpenUrlPubMed
  13. 13.↵
    2. Gralla RJ,
    3. Bosnjak SM,
    4. Hontsa A,
    5. Balser C,
    6. Rizzi G,
    7. Rossi G, et al.
    A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014; 25: 1333–9.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Zhang L,
    3. Lu S,
    4. Feng J,
    5. Dechaphunkul A,
    6. Chang J,
    7. Wang D, et al.
    A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018; 29: 452–8.
    OpenUrl
  15. 15.↵
    2. Aapro M,
    3. Hesketh PJ,
    4. Jordan K,
    5. Gralla RJ,
    6. Rossi G,
    7. Rizzi G, et al.
    Safety of an oral fixed combination of netupitant and palonosetron (NEPA): pooled data from the phase II/III clinical program. Oncologist. 2016; 21: 494–502.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Rizzi A,
    3. Campi B,
    4. Camarda V,
    5. Molinari S,
    6. Cantoreggi S,
    7. Regoli D, et al.
    In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant. Peptides. 2012; 37: 86–97.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Tonini G,
    3. Vincenzi B,
    4. Santini D.
    New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol. 2005; 1: 143–9.
    OpenUrlCrossRefPubMed
  18. 18.
    2. Stathis M,
    3. Pietra C,
    4. Rojas C,
    5. Slusher BS.
    Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012; 689: 25–30.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Rojas C,
    3. Raje M,
    4. Tsukamoto T,
    5. Slusher BS.
    Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014; 722: 26–37.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Roscoe JA,
    3. Heckler CE,
    4. Morrow GR,
    5. Mohile SG,
    6. Dakhil SR,
    7. Wade JL, et al.
    Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol. 2012; 30: 3389–95.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Aapro M,
    3. Fabi A,
    4. Nolè F,
    5. Medici M,
    6. Steger G,
    7. Bachmann C, et al.
    Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010; 21: 1083–8.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Roila F,
    3. Ruggeri B,
    4. Ballatori E,
    5. Del Favero A,
    6. Tonato M.
    Aprepitant versus dexamethasone for preventing chemotherapy induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol. 2014; 32: 101–6.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Roila F,
    3. Ruggeri B,
    4. Ballatori E,
    5. Fatigoni S,
    6. Caserta C,
    7. Licitra L, et al.
    Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015; 26: 1248–53.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Kosaka Y,
    3. Tanino H,
    4. Sengoku N,
    5. Minatani N,
    6. Kikuchi M,
    7. Nishimiya H, et al.
    Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer. 2016; 24: 1405–11.
    OpenUrl
  25. 25.↵
    2. Ito Y,
    3. Tsuda T,
    4. Minatogawa H,
    5. Kano S,
    6. Sakamaki K,
    7. Ando M, et al.
    Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol. 2018; 36: 1000–6.
    OpenUrlPubMed
  26. 26.↵
    2. Okada Y,
    3. Oba K,
    4. Furukawa N,
    5. Kosaka Y,
    6. Okita K,
    7. Yuki S, et al.
    One-day versus 3-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist. 2019; 24: 1593–600.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Yokoe T,
    3. Hayashida T,
    4. Nagayama A,
    5. Nakashoji A,
    6. Maeda H,
    7. Seki T, et al.
    Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist. 2019; 24: e347–57.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords